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Progressive elevations of fibroblastic growth factor 23
(FGF23) in chronic kidney disease may reduce serum
25-hydroxyvitamin D (25(OH)) and 1,25-dihydroxyvitamin D
(1,25(OH)2D) levels, via stimulation of 24-hydroxylase
(Cyp24a1)-mediated catabolism of these vitamin D
metabolites. To test this possibility, we measured serum
concentrations of 24,25-dihydroxyvitamin D (24,25(OH)2D), a
product of Cyp24a1 hydroxylation of 25(OH)D, in the Col4a3
knockout mouse, a model of Alport syndrome–derived
chronic kidney disease, and in patients with chronic kidney
disease of variable severity. There was an inverse correlation
between serum FGF23 and both 25(OH)D and 1,25(OH)2D in
the mouse model, but no significant relationship was
observed in the cross-sectional patient cohort. The FGF23-
dependent increase in Cyp24a1 mRNA expression in the
mouse kidneys was consistent with the possibility that FGF23
induces vitamin D catabolism. There was, however, a
reduction in serum 24,25(OH)2D levels, rather than the
expected elevation, in both the mice and patients with
chronic kidney disease. Low 25(OH)D and elevated FGF23
and parathyroid hormone levels were correlated with the
reduced serum 24,25(OH)2D concentrations of these patients.
Thus, we failed to find support for FGF23-mediated
catabolism of vitamin D metabolites in chronic kidney
disease assessed by 24,25(OH)2D levels.
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Chronic kidney disease (CKD) is associated with progressive
elevations of serum parathyroid hormone (PTH) and
fibroblastic growth factor 23 (FGF23) and reductions in 25-
hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D
(1,25(OH)2D) concentrations. The pathogenesis of CKD
has been viewed as arising from abnormalities of the
PTH–vitamin D axis, where reductions in 1,25(OH)2D lead
to secondary increases in PTH.1 The discovery of FGF23–
vitamin D endocrine network, however, has challenged this
conceptual framework by implicating FGF23 as the initial
hormonal adaptive response leading to phosphaturia,
reduced circulating 1,25(OH)2D levels, and secondary
hyperparathyroidism.2–7
FGF23 is a B32-kDa secreted protein, predominately
expressed in osteoblasts and osteocytes in bone,8–11 which
principally targets receptor complexes consisting of FGF
receptor (FGFR) 1, 3, or 4 and the transmembrane b-
glucuoronidase, a-Kl12–15 located in the kidney. PTH and
FGF23 have concordant effects to promote phosphaturia by
suppressing the expression of phosphate cotransporters Npt2a
and Npt2c, but have opposite effects on vitamin D metabolism,
where PTH stimulates Cyp27b1-mediated conversion of
25(OH)D to 1,25(OH)2D, and FGF23 inhibits Cyp27b1
activity and stimulates Cyp24a1, the enzyme responsible for
conversion of 25(OH)D and 1,25(OH)2D to inactive 24,25-
dihydroxyvitamin D (24,25(OH)2D) and 1,24,25-trihydroxyvi-
tamin D (1,24,25(OH)3D) metabolites, respectively.
16–22
1,25(OH)2D also stimulates FGF23 production in bone to
create a bone–kidney endocrine feedback loop.23
The primary role of FGF23 in the pathogenesis of
abnormal vitamin D metabolism and secondary hyperpar-
athyroidism in CKD, however, remains unproven, partly
because the contribution of FGF23-mediated suppression of
Cyp27b1 and stimulation of Cyp24a1 activity to the observed
reductions in serum 25(OH)D and 1,25(OH)2D levels in
CKD has not been defined. In addition, although FGF23
suppression of Cyp27b1-mediated synthesis of 1,25(OH)2D
is supported by concordant changes in FGF23, Cyp27b1
expression, and reductions in serum 1,25(OH)2D levels in
hereditary models of excess FGF23, the competing effects of
PTH and FGF23 on Cyp27b1 expression and activity in CKD
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create a more complex regulatory environment. Measure-
ment of Cyp27b1 and Cyp24a1 enzymatic activity in a
diseased kidney is technically challenging, but assays are
available to measure both 1,25(OH)2D and 24,25(OH)2D, the
end products of Cyp27b1- and Cyp24a1-mediated hydro-
xylation, respectively.
In the current study, to test the contributions of Cyp27b1-
mediated suppression and Cyp24a1-mediated catabolism of
vitamin D metabolites in CKD, we assessed serum 25(OH)D,
1,25(OH)2D, and 24,25(OH)2D levels in both a mouse model
of CKD7 and in a cohort of humans with impaired renal
function of varying severity. We predicted that circulating
24,25(OH)2D concentrations should be increased and
25(OH) and 1,25(OH)2D concentrations decreased propor-
tionate to the degree of renal insufficiency, if FGF23
stimulation of Cyp24a1 and inhibition of Cyp27b1 are
contributing to the abnormalities of vitamin D metabolism
in CKD.
RESULTS
Serum abnormalities in Col4a3/ mice
Consistent with our prior characterization of the Col4a3/
model of CKD,7 we found that by 12 weeks of age Col4a3/
mice had significant elevations of serum blood urea nitrogen
and creatinine concentrations. Col4a3/ mice also had
elevated serum phosphate levels and showed marked
elevations of both circulating PTH and FGF23 concentrations
compared with wild-type (WT) controls. The fractional
excretion of phosphate was also increased by approximately
threefold in Col4a3/ mice. We found that serum
blood urea nitrogen and creatinine positively correlated with
serum FGF23 levels (Figure 1a and b). In addition, serum
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Figure 1 |Pearson correlations between serum biochemical parameters in 12-week-old wild-type and Col4a3/ mice. Serum
fibroblastic growth factor 23 (FGF23) was positively correlated with increments in (a) serum blood urea nitrogen (BUN) and (b) creatinine.
(c) Serum parathyroid hormone (PTH) and FGF23 were positively correlated. (d) FGF23 was positively correlated with the fractional
excretion of phosphate (FEPi). Serum FGF23 levels were inversely correlated with (e) serum 25-hydroxyvitamin D (25(OH)D) and
(f) 1,25-dihydroxyvitamin D (1,25(OH)2D) levels.
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FGF23 positively correlated with serum PTH concentrations
(Figure 1c). The fractional excretion of phosphate also
correlated with serum FGF23 levels (Figure 1d). Serum
calcium and fractional excretion of calcium were also increased
in Col4a3/, suggesting an advanced stage of hyperparathy-
roidism. Serum alkaline phosphatase was slightly increased in
Col4a3/ mice, likely reflecting the high-turnover bone
disease that has been previously characterized in greater detail
in this CKD mouse model (Table 1).7
Abnormalities in vitamin D metabolism in Col4a3/
Next, we assessed serum vitamin D metabolite concentrations
in Col4a3/ and WT mice (Table 2). We found that serum
25(OH)D levels were significantly reduced in Col4a3/ mice
as were the serum 1,25(OH)2D levels, concordant with our
prior findings in these mice.7 We have also found that
elevations in serum FGF23 were inversely correlated with
both 25(OH)D and 1,25(OH)2D serum concentrations in
Col4a3/ mice (Figure 1e and f). In a multiple regression
analysis, which included serum FGF23, PTH, 1,25(OH)2D, blood
urea nitrogen, phosphate, and calcium, only FGF23 predicted the
changes in 25(OH)D (P¼ 0.02, b¼ 1.54, s.e.¼ 0.46).
To explore mechanisms for the observed alterations in
serum 25(OH)D, we measured the expression of Cyp27b1 in
the kidney, the enzyme responsible for conversion of
25(OH)D to 1,25(OH)2D. The message levels of Cyp27b1
were not different between WT and Col4a3/ mice at 6 and
8 weeks of age, but were increased by approximately threefold
in Col4a3/ mice compared with controls (Figure 2a) at 10
weeks of age, and further increased with renal damage
progression. Thus, Cyp27b1 mRNA may not reflect enzyme
activity as previously reported.24 Thus, we found no evidence
for a decrease in the expression of transcripts encoding the
enzymes responsible for producing 25(OH) or 1,25(OH)2D.
To further investigate the possibility of increased catabo-
lism as an explanation for the reduction in circulating
vitamin D metabolites, we assessed the expression of
Cyp24a1 message levels, the enzyme that converts
25(OH)D and 1,25(OH)2D into 24-hydroxylated derivatives
that are converted to calcitroic acid. Similar to Cyp27b1,
Cyp24a1 expression was not different between WT and
Col4a3/ mice at 6 and 8 weeks of age, but was increased in
the kidneys of Col4a3/ mice compared with WT controls
at 10 and 12 weeks of age (Figure 2b). The relative increase in
Cyp24a1 (B10-fold) was greater than that of Cyp27b1
(approximately threefold) resulting in a higher ratio of
Cyp24a1/Cyp27b1 in Col4a3/ mice by 10 weeks of age. To
determine the contribution of FGF23 to the alterations in
Cyp27b1 and Cyp24a1 message, we examined the expression
of Cyp27b1 and Cyp24a1 message in the kidney after genetic
ablation of FGF23 in Col4a3/ mice. We found that,
compared with Col4a3/ mice, loss of FGF23 in compound
Fgf23/Col4a3/ mice markedly increased Cyp27b1 ex-
pression, indicating that FGF23 was responsible for main-
taining Cyp27b1 at a relatively low level (Figure 2c). More
importantly, in the same setting, ablation of FGF23 restored
Cyp24a1 mRNA levels (Figure 2d) proving evidence that
FGF23 is likely responsible for upregulation of this enzyme.
To seek additional evidence for enhanced vitamin D
catabolism, we measured circulating 24,25(OH)2D levels in
Col4a3/ and WT mice as an index of Cyp24a1 activity.
Surprisingly, we found that 24,25(OH)2D levels were sig-
nificantly lower in Col4a3/ mice than that in WT controls
(Table 2). In addition, we found a strong negative correlation
between serum FGF23 and serum 24,25(OH)2D levels in
pooled data from Col4a3/ and WTmice (Figure 2e). These
results are in contrast to those anticipated if serum
24,25(OH)2D concentrations are an indicator of FGF23-
mediated Cyp24a1 hydroxylation of 25(OH)D.
Finally, we measured in the liver of Col3a4/ and WT
mice the message expression of two enzymes responsible for
25(OH)D production, Cyp2r1 and Cyp27a1. We found that
both transcripts were slightly, but not significantly, increased
in Col3a4/ mice compared with WT controls (Figure 2f).
Relationships between FGF23, PTH, and vitamin D
metabolism in humans
We stratified age- and disease-matched male patients with
low 25(OH)D levels into two groups based on an estimated
glomerular filtration rate (eGFR) threshold of o60ml/min
per 1.73m2 (Table 3). The eGFR, urine albumin creatinine
ratio, serum FGF23, serum PTH, and fractional excretion of
phosphate values were significantly greater in the group with
eGFR o60ml/min per 1.73m2 compared with the patients
with eGFR 460ml/min per 1.73m2. As expected based on
the selection criteria, we observed no difference in serum
25(OH)D levels in the two groups, both of which had average
Table 1 | Serum biochemistries in mice
WT Col4a3/
BUN (mg/dl) 19.9±0.7 59.3±9.2*
Serum creatinine (mg/dl) 0.45±0.03 0.83±0.16*
Serum PTH (pg/ml) 34±5 1827±479*
Serum FGF23 (pg/ml) 135±10 1216±199*
Serum PO4 (mg/dl) 6.5±0.5 9.5±0.5*
Serum Ca (mg/dl) 8.8±0.4 9.3±0.3
Fractional excretion of PO4 (%) 4.7±1.6 14.8±2.7*
Fractional excretion of Ca (%) 1.4±0.3 13.7±4.0
Alkaline phosphatase (IU/l) 67.0±8.6 90.2±10.9
Abbreviations: BUN, blood urea nitrogen; Ca, calcium; FGF23, fibroblast growth
factor 23; PO4, phosphorus; PTH, parathyroid hormone; WT, wild type.
Values are expressed as mean±s.e.m. from at least 13 mice per group. Comparisons
were performed using one-way analysis of variance and post-hoc Fisher’s test.
*Po0.05 vs. WT.
Table 2 | Serum vitamin D metabolite concentrations in mice
WT Col4a3/
25(OH)D (ng/ml) 44.1±3.2 24.8±2.6*
1,25(OH)2D (pg/ml) 101±19 70±19*
24,25(OH)2D (ng/ml) 15.7±1.0 4.1±1.1*
Abbreviations: 1,25(OH)2D, 1,25-dihydroxyvitamin D; 24,25(OH)2D, 24,25-dihydrox-
yvitamin D; 25(OH)D, 25-hydroxyvitamin D.
Values are expressed as mean±s.e.m. from at least 13 mice per group. Comparisons
were performed using one-way analysis of variance and post-hoc Fisher’s test.
*Po0.05 vs. WT.
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values below the lower limit of normal. Serum 1,25(OH)2D
concentrations, however, were in the normal range and did
not differ between the two groups.
We found a strong negative correlation between eGFR and
FGF23 (Figure 3a) and a positive correlation between serum
creatinine and FGF23 (Figure 3b), as well as a strong positive
correlation between serum FGF23 and PTH levels (Figure
3c). We also observed a positive correlation between FGF23
and fractional excretion of phosphate (Figure 3d). Unlike the
mouse model of CKD, however, we did not find a significant
correlation between FGF23 and either 25(OH)D (Figure 3e)
or 1,25(OH)2D levels (Figure 3f) in the cohort of humans
subjects, possibly due to the low circulating 25(OH)D levels
used to select these patients. When we examined patients
with FGF23 levels 4100 ng/ml (i.e., a level typical of more
advanced CKD patients), FGF23 did negatively correlate with
baseline 1,25(OH)2D levels (r¼ 0.56, P¼ 0.02, n¼ 14).
Similar to the findings in the mouse CKD model, however,
serum 24,25(OH)2D levels were significantly lower in
patients with eGFR o60ml/min per 1.73m2 compared with
patients with eGFR X60ml/min per 1.73m2. Indeed, the
serum 24,25 (OH)2D levels were twofold lower in the CKD
4 14
WT
a
Cy
p2
7b
1 
m
R
N
A 
ex
pr
es
sio
n
Cy
p2
7b
1 
m
R
N
A 
ex
pr
es
sio
n
24
,2
5(O
H)
2D
 
(ng
/m
l)
6
Age (weeks)
*
*
*
*
*a
*a
*
3
2
1
0
120
8 10 12
Col4a3–/–
WT
Cy
p2
4a
1 
m
R
N
A 
ex
pr
es
sio
n
Cy
p2
4a
1 
m
R
N
A 
ex
pr
es
sio
n
m
R
N
A 
ex
pr
es
sio
n
6
Age (weeks)
WT
0
9
a
a
8 10 12
Col4a3–/–
Col4a3–/–Col4a3–/–
Cyp2r1 Cyp27a1
Fgf23–/–
Col4a3–/–
Fgf23–/–WT
50
WT
Col4a3–/–
Fgf23–/–
Col4a3–/–
Fgf23–/–
12
10
8
6
4
2
8
7
6
5
4
3
2
1
0
2.0
100
80
60
40
20
20
0
r=– 0.67, P=0.0004; R2 = 0.4418
16
14
12
10
8
6
4
2
0
75
250
500
750
2500
5000
7500
FGF23 (pg/ml)
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
b
c d
e f
*
Figure 2 |Regulation of vitamin D metabolism in 12-week-old wild-type (WT) and Col4a3/ mice. Time-course expression of (a)
Cyp27b1 and (b) Cyp24a1 in the kidney of WT and Col4a3/ mice. Both Cyp27b1 and Cyp24a1 message expression age-dependently
increased in Col4a3/ mice compared with WT controls. Expression of (c) Cyp27b1 and (d) Cyp24a1 in the kidney of 12-week-old WT,
Col4a3/Fgf23/, and compound Fgf23/Col4a3/ mice. NX4, *Po0.05 vs. WT, aPo0.05 vs. Col4a3/ mice. mRNA expression
normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and relative to values in WT controls. (e) Relationship between serum
fibroblastic growth factor 23 (FGF23) and 24,25-dihydroxyvitamin D (24,25(OH)2D) levels. There was a significant inverse correlation
between serum FGF23 and serum 24,25(OH)2D levels. (f) Expression of Cyp2r1 and Cyp27a1 in the liver. mRNA expression normalized by
GAPDH and relative to values in WT controls. There was no significant difference in expression of the enzymes that generate 25-
hydroxyvitamin D in Col4a3/ mice compared with WT mice.
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Table 3 | Serum biochemical parameters in patients grouped by eGFR
eGFR X60 (ml/min per 1.73m2) (n=14) eGFR o60 (ml/min per 1.73m2) (n=14) P-value
African American (%) 55 44 0.6946
Diabetes mellitus (%) 42 42 1
Age (years) 62.57±6.46 65.71±8.49 0.1587
eGFR (ml/min per 1.73m2) 85.97±14.66 35.65±6.4 o0.0001
BMI (kg/m2) 30.64±5.54 28.88±5.87 0.4229
Urine ACR (mg/g) 0.13±0.16 1.79±2.37 0.0093
Serum FGF23 (pg/ml) 80.92±35.42 152±34.81 o0.0001
Serum 25(OH)D (ng/ml) 11.6±4 14.6±5 0.0677
Serum 1,25(OH)2D (pg/ml) 44±19 43±19 0.8329
Serum 24,25(OH)2D (ng/ml) 1.24±1 0.65±0.5 0.0683
Serum PTH (pg/ml) 58±28 167±117 0.0007
Serum alkaline phosphatase (IU/l) 84.71±25.71 95.57±23.94 0.7304
Fractional excretion of calcium 0.69±0.65 1.15±1.85 0.2140
Fractional excretion of PO4 12.26±4.03 29.92±8.63 o0.0001
Abbreviations: ACR, albumin creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23; 1,25(OH)2D, 1,25-
dihydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; 25(OH)D; 25-hydroxyvitamin D; PO4, phosphorus; PTH, parathyroid hormone.
Categorical variables are presented as percentage and continuous variables as mean±s.d. Fisher’s exact test was used for the variable African American, w2 test for the
variable diabetes mellitus. Unpaired t-test was used for the variables FGF23, serum 25(OH)D, and BMI; Mann–Whitney U-test was used for the rest of the continuous variables.
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Figure 3 |Regression analysis in human subjects with varying degrees of renal impairment. Fibroblastic growth factor 23 (FGF23) is
(a) inversely correlated with estimated glomerular filtration rate (eGFR) and (b) positively correlated with serum creatinine. (c) Serum parathyroid
hormone (PTH) and FGF23 are positively correlated. (d) FGF23 is also positively correlated with the fractional excretion of phosphate (PO4).
Neither (e) 25-hydroxyvitamin D (25(OH)D) nor (f) 1,25-dihydroxyvitamin D (1,25(OH)2D) are significantly correlated with FGF23.
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group compared with the group with ‘normal’ renal function
(i.e., 0.65 vs. 1.24 ng/ml).
Overall, the serum 24,25(OH)2D, 1,25(OH)2D, and FGF23
levels were 15-, 2-, and 1.6-fold higher, and PTHB50% lower,
respectively, in WTmice compared with humans with an eGFR
X60ml/min per 1.73m2. In the setting of impaired renal
function, these same parameters were 8-, 1.6-, 8-, and 11-fold
higher, respectively, in the Col4a3/ mice with CKD com-
pared with subjects with an eGFR o60ml/min per 1.73m2.
Compared with controls, the reduction in the 24,25(OH)2D
levels was fourfold greater and the elevation in FGF23 and PTH
was approximately fourfold higher as observed in the mouse
model of CKD than the respective changes in humans with
CKD, suggesting that the mouse model is more sensitive to
alterations in mineral metabolism markers. This finding is
similar to the accentuated alterations in FGF23 and vitamin D
metabolism observed in Hyp mice compared with human
patients with X-linked hypophosphatemic rickets.25
To determine predictors of serum 24,25(OH)2D levels in
the human subjects, we performed univariate (Table 4,
Figure 4) and multivariable regression analyses (Table 5).
Serum PTH, 25(OH)D, FGF23, creatinine, and urinary
fractional excretion of phosphorus were significant predic-
tors of serum 24,25(OH)2D levels in simple regression
analysis (Table 4). An inverse relationship was present
between FGF23, PTH, and creatinine and 24,25(OH)D2 levels
(Figure 4). In contrast, a positive association was observed
between serum 25(OH)D and 24,25(OH)2D levels, suggesting
that low substrate level leads to low 24,25(OH)2D levels.
These predictor variables along with the interaction terms
between them were utilized in a multiple regression model.
Collinearity statistics for all of the predictor variables entered
in the multiple linear regression analysis indicated that in all
cases, tolerance values were 40.7 and the VIF was o2. This
excludes any serious problem with multicollinearity.
The final model predicting serum 24,25(OH)2D level
consisted of FGF23, PTH, and 25(OH)D without any
interaction terms (Table 5). These variables together explained
55% of the variations in serum 24,25(OH)2D level
(Radj
2 ¼ 0.5548), and the overall relationship was significant,
F(3,24)¼ 10.97, P¼ 0.0002. With other variables held constant,
serum 24,25(OH)2D level is negatively related to FGF23
(t21¼2.26, P¼ 0.0349) and PTH (t21¼2.55, P¼ 0.0185),
and positively related to 25(OH)D (t21¼ 3.40, P¼ 0.0027).
The final model holds the following equation: estimated
24,25(OH)2D¼ 0.14307þ 0.03157 25(OH)D0.00126 PTH
0.00236 FGF23. The model suggested that a rise in serum
PTH and FGF23 by 10pg/ml would decrease 24,25(OH)2D
levels by 1% and 2%, respectively. On the other hand, a 10-ng/
ml rise in serum 25(OH)D level would increase 24,25(OH)2D
level by 32%.
DISCUSSION
In the current study, we measured serum concentrations of
24,25(OH)2D and assessed the relationships between serum
24,25(OH)2D and FGF23, PTH, 25(OH)D, and 1,25(OH)2D
concentrations in both mice and humans with CKD to
determine whether FGF23 stimulates the catabolism of
25(OH)D and 1,25(OH)2D in CKD.
2,26,27 Our initial findings
supported a potential role of FGF23 in the reductions of
1,25(OH)2D as well as 25(OH)D in CKD. First, the ratio
of Cyp24a1 to Cyp27b1 message is increased in the kidney of
Col4a3/ mice. Second, serum FGF23 levels were inversely
correlated with both serum 25(OH)D and 1,25(OH)2D in
Col4a3/ mice, consistent with FGF23-mediated degradation
of these metabolites. Interestingly, we did observe an inverse
correlation between serum FGF23 and 1,25(OH)D, but not
25(OH)D, levels in the human subjects examined in this study.
However, others have observed a correlation between
decreased eGFR and reduced 25(OH)D and increased FGF23
concentrations.28,29 We were unable to find direct evidence,
however, for increased Cyp24a1 activity in Col4a3/ mice or
the human subjects with CKD. Indeed, serum 24,25(OH)2D
levels, the initial product of Cyp24a1-mediated hydroxylation
of 25(OH)D, were suppressed in Col4a3/ mice and human
subjects with CKD, rather than elevated.
The most conservative interpretation of these findings is
that reductions in serum 25(OH)D and 1,25(OH)2D in CKD
are not caused by FGF23-mediated stimulation of Cyp24a1
catabolism. In this scenario, the increase in expression of
Cyp24a1 message level in the kidney does not represent an
increase in enzymatic activity. One possible explanation may
be that elevated PTH decreases Cyp24a1 mRNA stability.30
Consistent with this possibility, the message expression of
Cyp27b1 also does not correlate with enzymatic activity in
other states of combined PTH and FGF23 excess.24 If so, low
circulating levels of 1,25(OH)2D and 24,25(OH)2D in CKD
might result from a decreased total enzymatic activity in the
diseased kidney, which is the principal source of circulating
24,25(OH)2D.
31 Alternatively, a more speculative conclusion
is that Cyp24a1 activity is increased in CKD in response to
increased serum FGF23, and that serum 24,25(OH)2D is not
elevated because of its rapid clearance and conversion to
calcitroic acid.32 If so, 24,25(OH)2D may not be a marker of
Table 4 | Univariate analysis of serum 24,25(OH)2D
Predictor variables b s.e. (b) P-value
Age (years) 0.0054 0.00857 0.5285
BMI (kg/m2) 0.0016 0.01145 0.8899
Serum PTH (pg/ml) 0.0018 0.00052 0.0016
Diabetes mellitus 0.09148 0.13541 0.5061
Serum FGF23 (pg/ml) 0.0029 0.00121 0.0225
Serum 25(OH)D (ng/ml) 0.02796 0.01237 0.0336
Serum 1,25(OH)2D (pg/ml) 0.00416 0.0347 0.2437
Serum Ca (mg/dl) 0.37953 0.22884 0.1108
Serum PO4 (mg/dl) 0.06079 0.09631 0.5344
Serum creatinine (mg/dl) 0.1981 0.09307 0.0442
eGFR (ml/min per 1.73m2) 0.0390 0.00228 0.1009
Urine ACR (mg/g) 0.0199 0.03495 0.5734
Fractional excretion of PO4 (%) 0.01204 0.00549 0.0392
Fractional excretion of Ca (%) 0.02414 0.04732 0.6149
Abbreviations: ACR, albumin creatinine ratio; BMI, body mass index; Ca, calcium;
eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23;
1,25(OH)2D, 1,25-dihydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D;
25(OH)D, 25-hydroxyvitamin D; PO4, phosphorus; PTH, parathyroid hormone.
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increased Cyp24a1 activity in CKD. Consistent with this
possibility, chronic 1,25(OH)2D administration to rats
in vivo increases the in vitro conversion of 25(OH)D to
24,25(OH)2D, but at the same time decreases circulating
24,25(OH)2D levels.
33 Further studies will be needed to
distinguish between these two interpretations.
Limited 25(OH)D substrate might also influence the
production of 24,25(OH)2D.
34 In multiple regression analysis
in human subjects, low 25(OH)D was a strong predictor of
reductions in 24,25(OH)2D. We found no alterations in
hepatic enzymes that generate 25(OH)D. Interestingly, serum
24,25(OH)2D levels were markedly higher in WT mice than
in humans with normal renal function. This may be due to
genetic differences between mice and humans. Alternatively,
the relatively high dietary content of vitamin D in rodent
food may account for the higher 24,25(OH)2D levels in both
CKD and WT mice compared with humans with CKD and
preserved renal function. Finally, reductions in serum
25(OH)D as a function of CKD severity might also result
from the failure of a diseased kidney to recycle 25(OH)D
from the glomerular ultrafiltrate back into proximal tubular
cells for 1,25(OH)2D synthesis, and back into the circulation
to maintain serum 25(OH)D levels.
The finding of low levels of 24,25(OH)2D in CKD has also
been found in patients with CKD by Ishimura et al.34 and in
the Seattle Kidney Study cohort (Ian H. DeBoer, personal
communication). The clinical significance of low serum
24,25(OH)2D concentrations is not clear. 24,25(OH)2D may
have a role in bone mineralization and fracture repair.35 The
low 24,25(OH)2D was associated with increased mortality in
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Figure 4 |Determinants of serum 24,25-dihydroxyvitamin D (24,25(OH)2D) levels in human subjects. Serum 24,25(OH)2D was
positively correlated with 25-hydroxyvitamin D (25(OH)D) (a) and inversely related to serum parathyroid hormone (PTH) (b), fibroblastic
growth factor 23 (FGF23) (c), serum creatinine (d), fractional excretion of phosphate (e).
Table 5 |Multivariable analysis of serum 24,25(OH)2D
Predictor variables b s.e. (b) P-value
Serum PTH (pg/ml) 0.0012 0.00049 0.0185
Serum FGF23 (pg/ml) 0.0023 0.00121 0.0349
Serum 25(OH)D (ng/ml) 0.03157 0.01237 0.0027
Abbreviations: FGF23, fibroblast growth factor 23; 24,25(OH)2D, 24,25-dihydroxy-
vitamin D; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone.
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the Seattle Kidney Study cohort, but this could also reflect the
effects of FGF23, which was a determinant of 24,25(OH)2D
levels and is associated with increased mortality in CKD.36
Our results suggest a complex interplay between elevated
PTH and FGF23 on Cyp27b1 functions in CKD. In this
regard, we found that the kidney expression of Cyp27b1 was
fourfold high in the Col4a3/ CKD model, possibly
reflecting actions of elevated PTH to stimulate Cyp27b1
expression, but Cyp27b1 was increased over 50-fold after
ablation of FGF23 in Col4a3/ mice. In spite of increased
PTH, a negative correlation was observed between FGF23 and
1,25(OH)2D levels in Col4a3
/ mice, consistent with the
possibility that FGF23 and PTH have opposite effects on the
production of 1,25(OH)2D. Other reports indicate that the
stimulatory effects of PTH may be offset by the suppressive
effects of FGF23 on Cyp27b1 enzymatic activity at the
posttranscriptional levels.7,24,26 The importance of FGF23 on
vitamin D metabolism is supported by the observation that
treatment of a rat model of anti-GBM nephritis with a
neutralizing anti-FGF23 antibody increases serum
1,25(OH)2D levels and Cyp27b1 expression and reduces
Cyp24a1 expression.27
Our findings suggest that FGF23 and PTH have
concordant effects on phosphate homeostasis, as FGF23 is
positively correlated with PTH in both a homogenous mouse
model of CKD and a more diverse group of human subjects
with varying degrees of renal impairment. This positive
association between PTH and FGF23 is consistent with other
reports showing a strong association between elevated FGF23
levels and the severity of HPT in CKD and other
disorders.13,37,38 The mechanism of FGF23 and PTH co-
regulation are unclear, and direct effects of PTH to stimulate
FGF23 expression in bone, indirect effects of PTH to
stimulate FGF23 through PTH-mediated increase in
1,25(OH)2D levels, and FGF23 effects to suppress PTH
directly or to indirectly stimulate PTH because of FGF23-
mediated suppression of 1,25(OH)2D have been proposed.
39
Our study has several limitations. With regard to the
mouse studies, we lack measurements of Cyp27b1 or
Cyp24a1 enzymatic activity and important genetic and
dietary differences in these models may limit extrapolating
findings to humans. Observations in the mouse CKD model
also highlight the conflicting regulatory networks, where
initial FGF23-mediated suppression of 1,25(OH)2D may lead
to progressive elevations in PTH, which in turn may further
stimulate both FGF23 and 1,25(OH)2D levels. Further studies
are needed to assess the interdependent regulation of PTH,
FGF23, and 1,25(OH)2D in CKD. With regard to the human
studies, the sample size is small, the patient population is
heterogeneous, and were preselected based on low 25(OH)D
levels, which may have led to a failure to observe relation-
ships between FGF23, PTH, and vitamin D metabolites that
are functionally important. However, the number of patients
examined is insufficient for the accurate assessment of all the
potential predictors of 24,25(OH)2D levels. Our data in both
mice and human models of CKD fail to explain the reduction
in 25(OH)D levels, which was measured by immunoassay,
which may also detect other vitamin D metabolites.40
Perhaps assessment of 25(OH)D by HPLC or free
25(OH)D might provide different results. We need additional
assessments of pathways leading to 25(OH)D production, as
well as vitamin D catabolic pathways, such as 1,24,25(OH)3D
levels, 24,25(OH)2D levels after treatment with vitamin D
analogs, and calcitroic acid (1a-hydroxy-23-carboxy-
24,25,26,27-tetranorvitamin D) production.41
In summary, we found that the measurements of
24,25(OH)2D levels fail to evaluate the contribution of
FGF23-driven increases in 24-hydroxylase in 25(OH)D
catabolism in CKD. Indeed, circulating 24,25(OH)2D levels
were not elevated in either mice or humans with CKD. The
significance of this unexpected negative finding remains to be
established.
MATERIALS AND METHODS
Animals and genotyping
All mice were maintained on a standard diet (7912, Harlan Teklad,
Madison, WI). Animal care and protocols were in accordance
with the guidelines established by the University of Tennessee
Institutional Animal Care and Use Committee as detailed in the
‘Guide for Care and Use of Laboratory Animals,’ prepared by
the Institute on Laboratory Animal Resources, National Research
Council (Department of Health & Human Services Publication NIH
86-23, National Academy Press, 1996).
Heterozygous Col4a3þ / mice were obtained from Jackson
Laboratories (Westgrove, PA). Ear biopsies were collected to
genotype the mice. The REDExtract-N-Amp Tissue PCR Kit
(Sigma-Aldrich, St. Louis, MO) was used for DNA extraction and
PCR amplification. Mice were genotyped for col4a3 mutation
and PCR was repeated in all mice after killing to exclude artifacts
and ensure the correct genotype.9
Serum biochemistry
Serum samples from mice were collected by intracardiac exsangui-
nation. Calcium was measured using a Calcium CPC Liquicolor Kit
(Stanbio Laboratories, Boerne, TX) and phosphorus was measured
using the phosphomolybdylate–ascorbic acid method.9 PTH levels
were measured using the Mouse Intact PTH ELISA kit (Immutopics,
Carlsbad, CA). 1,25(OH)2D and 25(OH)D levels were measured
using the vitamin D EIA Kits (Immunodiagnostic Systems, Fountain
Hills, AZ).
FGF23 levels were measured in both mice and humans using the
FGF23 ELISA kit (Kainos Laboratories, Tokyo, Japan). 24,25(OH)2D
level was measured in both mice and human samples by
Heartland Assays LLC (Ames, IA) according to previously published
procedures.31,42 25(OH)D levels were measured in humans by
immunochemical illuminometric assay, albumin by bromcresol
green assay, and creatinine by isotope dilution mass spectrometry
traceable Jaffe´ method from Roche (compensated Jaffe´, Roche
Diagnostics, Mannheim, Germany).
RT-PCR
Total RNAs were isolated using TRI reagent and first-strand cDNA
was synthesized from the kidney or liver RNAs according to a
previously published method.43 The iCycler iQ Real-Time PCR
Detection System and iQ SYBR Green Supermix (Bio-Rad, Hercules,
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CA) were used for real-time quantitative PCR analysis. The
expression was normalized by glyceraldehyde-3-phosphate dehy-
drogenase in the same sample and expressed as fold change of WT.
Human subjects
The human cohort in the trial includes 53 patients with vitamin D
deficiency (serum 25(OH)D level o20 ng/ml) identified between
April 2009 and July 2010. The study was approved by the
institutional review board of Veterans Affairs Medical Center,
Memphis, TN. Inclusion criteria for the study were the following:
men and women over the age of 18 years and serum 25(OH)D levels
o20 ng/ml. Exclusion criteria included the following: an eGFR
o15ml/min per 1.73m2 or chronic dialysis patients; receipt of any
form of vitamin D supplementation; the presence of cirrhosis,
sarcoidosis, lymphoma, malabsorption syndrome, solid organ
transplant, or hypoparathyroidism; and the use of medications
known to alter vitamin D metabolism, including rifampin,
corticosteroids, anti-epileptics, phosphate binders, and calcimi-
metics. Patients with CKD were matched with patients with normal
renal function based on several matching variables in 1:1 basis. The
matching variables were age (within 5 years), race, gender, and
diabetes mellitus. Fourteen patients with CKD were matched with
14 patients with normal renal function.
Urinary protein excretion was measured as a ratio of spot urine
protein–creatinine (UPC) ratio or as spot urine albumin–creatinine
ratio (ACR) (ACR¼UPC(1.054) 0.596). The eGFR was calculated
according to the four-variable formula used in the Modification of
Diet in Renal Disease Study. Body mass index was calculated by
person’s weight in kilograms divided by their height in square
meters.
Statistical analysis
For the mouse studies differences between the two groups were
tested by Student’s t test using the Statistica software (Statsoft, Tulsa,
OK). The differences were considered statistically significant at
Po0.05. Pearson correlations and multiple regression analysis were
performed to examine the relationship between the measured serum
parameters.
For the human subjects, continuous variables were presented as
means and standard deviations and categorical variables as percen-
tages, unless otherwise specified. Normally distributed continuous
variables were compared using unpaired t-test and non-normally
distributed continuous variables with Mann–Whitney U-test. To
evaluate the factors affecting the 24,25(OH)2D level, univariate
analyses were performed using the following predictor variables: age,
race, diabetes mellitus, body mass index, serum calcium, phos-
phorus, creatinine, FGF23, PTH, 25(OH)D, 1,25(OH)2D, eGFR, and
urine albumin–creatinine ratio level. The variable, 24,25(OH)2D,
was log transformed to attain normal distribution. All tests were
two-sided and P-valueo0.05 was considered significant. Statistical
analysis was conducted using SAS version 9.2 (SAS Institute,
Cary, NC).
DISCLOSURE
LDQ is a consultant and speaker for Amgen. All the other authors
declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by the NIH grant RO1-AR45955 from
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases.
REFERENCES
1. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for
suppressing parathyroid hormone in end-stage renal disease: time for a
paradigm shift? Nat Clin Pract 2009; 5: 24–33.
2. Quarles LD. The bone and beyond: ‘Dem bones’ are made for more than
walking. Nat Med 2011; 17: 428–430.
3. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23)
predicts progression of chronic kidney disease: the Mild to Moderate
Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600–2608.
4. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates
hyperphosphatemia but accentuates calcitriol deficiency in chronic
kidney disease. J Am Soc Nephrol 2005; 16: 2205–2215.
5. van Husen M, Fischer AK, Lehnhardt A et al. Fibroblast growth factor 23
and bone metabolism in children with chronic kidney disease. Kidney Int
2010; 78: 200–206.
6. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated
before parathyroid hormone and phosphate in chronic kidney disease.
Kidney Int 2011; 79: 1370–1378.
7. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23
changes and mineral metabolism abnormalities in a mouse model of
chronic kidney disease. J Bone Miner Res 2011.
8. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23
expression but not degradation by PHEX. J Biol Chem 2003; 278:
37419–37426.
9. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice.
Am J Physiol Endocrinol Metab 2006; 291: E38–E49.
10. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in
phosphate homeostasis and pathogenesis of disordered mineral
metabolism in chronic kidney disease. Semin Dial 2007; 20: 302–308.
11. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast
growth factor, FGF-23, preferentially expressed in the ventrolateral
thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277:
494–498.
12. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth
factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120–6123.
13. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical
FGF receptor into a specific receptor for FGF23. Nature 2006; 444:
770–774.
14. Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms
for the endocrine actions of fibroblast growth factor-23. Endocrinology
2005; 146: 4647–4656.
15. Li H, Martin AC, David V et al. Compound deletion of FGFR3 and FGFR4
partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol
Metab 2011; 300: E508–E517.
16. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23
demonstrates an essential physiological role of FGF23 in phosphate and
vitamin D metabolism. J Clin Invest 2004; 113: 561–568.
17. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of
FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl
Acad Sci USA 2001; 98: 6500–6505.
18. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant
hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int
2001; 60: 2079–2086.
19. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-
independent FGF23 actions in regulating phosphate and vitamin D
metabolism. Am J Physiol Renal Physiol 2005; 289: F1088–F1095.
20. Tomiyama K, Maeda R, Urakawa I et al. Relevant use of Klotho in FGF19
subfamily signaling system in vivo. Proc Natl Acad Sci USA 2010; 107:
1666–1671.
21. Beckman MJ, Tadikonda P, Werner E et al. Human 25-hydroxyvitamin
D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996; 35:
8465–8472.
22. Hoenderop JG, Chon H, Gkika D et al. Regulation of gene expression by
dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1 alpha-hydroxylase
knockout mice. Kidney Int 2004; 65: 531–539.
23. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-
regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;
17: 1305–1315.
24. Yuan B, Xing Y, Horst RL et al. Evidence for abnormal translational
regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in
the hyp-mouse. Endocrinology 2004; 145: 3804–3812.
25. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and
disordered phosphorus homeostasis. J Bone Miner Res 2003; 18:
1227–1234.
26. Helvig CF, Cuerrier D, Hosfield CM et al. Dysregulation of renal vitamin D
metabolism in the uremic rat. Kidney Int 2010; 78: 463–472.
Kidney International (2012) 82, 1061–1070 1069
B Dai et al.: FGF23 effects on vitamin D catabolism o r ig ina l a r t i c l e
27. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative
role of FGF23 in the abnormal renal phosphate handling and vitamin D
metabolism in rats with early-stage chronic kidney disease. Kidney Int
2010; 78: 975–980.
28. de Boer IH, Katz R, Chonchol M et al. Serum 25-hydroxyvitamin D and
change in estimated glomerular filtration rate. Clin J Am Soc Nephrol
2011; 6: 2141–2149.
29. Chonchol M, Cigolini M, Targher G. Association between 25-
hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic
patients with mild kidney dysfunction. Nephrol Dial Transplant 2008; 23:
269–274.
30. Zierold C, Mings JA, DeLuca HF. Parathyroid hormone regulates
25-hydroxyvitamin D(3)-24-hydroxylase mRNA by altering its stability.
Proc Natl Acad Sci USA 2001; 98: 13572–13576.
31. Horst RL, Littledike ET, Gray RW et al. Impaired 24,25-dihydroxyvitamin
D production in anephric human and pig. J Clin Invest 1981; 67:
274–280.
32. Kumar R, Wiesner R, Scott M et al. Physiology of 24,25-dihydroxyvitamin
D3 in normal human subjects. Am J Physiol 1982; 243: E370–E374.
33. Halloran BP, Bikle DD, Levens MJ et al. Chronic 1,25-dihydroxyvitamin
D3 administration in the rat reduces the serum concentration of
25-hydroxyvitamin D by increasing metabolic clearance rate.
J Clin Invest 1986; 78: 622–628.
34. Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-
dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D
in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55:
1019–1027.
35. St-Arnaud R. CYP24A1-deficient mice as a tool to uncover a biological
activity for vitamin D metabolites hydroxylated at position 24. J Steroid
Biochem Mol Biol 2010; 121: 254–256.
36. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of
mortality and end-stage renal disease in patients with chronic kidney
disease. JAMA 2011; 305: 2432–2439.
37. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho
gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51.
38. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of
Klotho protein in brain, kidney, and reproductive organs of mice. Cell
Struct Funct 2004; 29: 91–99.
39. Haussler MR, Haussler CA, Whitfield GK et al. The nuclear vitamin D
receptor controls the expression of genes encoding factors which feed
the ‘Fountain of Youth’ to mediate healthful aging. J Steroid Biochem Mol
Biol 2010; 121: 88–97.
40. Lips P, Chapuy MC, Dawson-Hughes B et al. An international comparison
of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9:
394–397.
41. Inouye K, Sakaki T. Enzymatic studies on the key enzymes of vitamin D
metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24).
Biotechnol Annu Rev 2001; 7: 179–194.
42. Horst RL, Shepard RM, Jorgensen NA et al. The determination of 24,25-
dihydroxyvitamin D and 25,26-dihydroxyvitamin D in plasma from normal
and nephrectomized man. J Lab Clin Med 1979; 93: 277–285.
43. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Dmp1-null mice.
Am J Physiol Endocrinol Metab 2008; 295: E254–E261.
This work is licensed under the Creative Com-
monsAttribution-NonCommercial-NoDerivative
Works3.0UnportedLicense.Toviewa copyof this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
1070 Kidney International (2012) 82, 1061–1070
or ig ina l a r t i c l e B Dai et al.: FGF23 effects on vitamin D catabolism
